

EPIX Pharmaceuticals, Inc.  
Form SC 13G/A  
February 17, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13G  
Under the Securities Exchange Act of 1934  
(Amendment No. 2)\*  
EPIX PHARMACEUTICALS, INC.  
(Name of Issuer)  
Common Stock  
(Title of Class of Securities)  
26881Q309  
(CUSIP Number)  
[December 31, 2008]**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

This Amendment No. 2 amends and supplements the Statement on Schedule 13G electronically filed with the Securities and Exchange Commission (the Commission ) on December 21, 2006 and subsequent Amendment No. 1 filed with the Commission on February 12, 2008 with respect of the ownership of securities of EPIX Pharmaceuticals Inc. (the Initial Statement ).

The undersigned hereby amends and supplements Item 4 of Initial Statement with the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Initial Statement).

CUSIP No. 26881Q309

**1** NAMES OF REPORTING PERSONS. I.R.S. Identification Nos. of above persons (entities only)  
GlaxoSmithKline plc

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

**2**  
(a)   
(b)

**3** SEC USE ONLY

**4** CITIZENSHIP OR PLACE OF ORGANIZATION  
England and Wales

	<b>5</b>	SOLE VOTING POWER
NUMBER OF		4,559,235
SHARES	<b>6</b>	SHARED VOTING POWER
BENEFICIALLY		
OWNED BY		-0-
EACH	<b>7</b>	SOLE DISPOSITIVE POWER
REPORTING		
PERSON		4,559,235
WITH:	<b>8</b>	SHARED DISPOSITIVE POWER
		-0-

**9** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
4,559,235

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

10.9%

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

CUSIP No. 26881Q309

**Item 1.**

(a) Name of Issuer

(b) Address of Issuer's Principal Executive Offices

**Item 2.**

(a) Name of Person Filing

(b) Address of Principal Business Office or, if none, Residence

(c) Citizenship

(d) Title of Class of Securities

(e) CUSIP Number

**Item 3.** n/a

CUSIP No. 26881Q309

**Item 4. Ownership**

The information in items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby incorporated by reference.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person**

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company**

**Item 8. Identification and Classification of Members of the Group**

**Item 9. Notice of Dissolution of Group**

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GlaxoSmithKline plc

By: /s/ Victoria A. Whyte  
Victoria A. Whyte  
Deputy Company Secretary

5